Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The fact that they cannot nail down a contract of any size makes one think there is a significant problem with either product , process or price.
For 2020,
I would love to see Dr Hayward step back and let someone else take the helm.
Sell off or spin off the Certain T platform as well as all the assets, customers, patents, ect.
Focus on the biotech space, expand their footprint thru merger or acquisitions
I'm not asking for much, lol
"The Company’s majority-owned subsidiary", does anybody know what percentage they do own?
From the most recent 10Q:
Assuming the Company obtains FDA approval for one or more of its product candidates, which the Company does not expect to receive until 2023 at the earliest, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and development of additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing.
AMRN is a much better buy, Dilution is in the rear view mirror and FDA approval by years end.
So Kalergis is offering a share with 2 warrants for 66 cents? How soon to delisting?
Would we be in this situation with the Nasdaq if TheraCann had paid us in a timely manner?
So far this has been a real disappointing investment. LineaRX looks like a promising product but everything else looks like a bust. TheraCann in particular is a stunning disappointment. At this point, I'm wondering if its even worth averaging down? Opinions welcome.thanks
Why would anybody buy shares in this company? Management is doing absolutely nothing to support the share price.
Does anybody know if this is a pilot project or an actual revenue producing account?
Now this is what the NWBO web site should look like:
https://www.ivybraintumorcenter.org/
Does anybody think this Linea RX will get spun off eventually?
https://www.linearxdna.com/
This lineaRX is starting to get interesting. I wonder what the profit margins are on this?
yes, on the surface it is great news, especially for Dr H, curious how the final agreement turns out. How exclusive is this deal? Are we allowed to work with other companies in this space?
Does anybody know what the long tail would look like for just standard of care? thanks
Does anybody know how many charging station NEO has available?
Does anybody know what their maximum manufacturing capacity is before they need to build out? thanks
Here is a interesting read on the current state of cancer vaccines. DCVac-L gets mentioned on page 53.
https://web.wpi.edu/Pubs/E-project/Available/E-project-081418-102424/unrestricted/CancerVaccinesIQP.pdf
Buyout or Reverse split. One of the two
Does anybody know how much debt and cash Marker is bringing to the table for this merger?
Anybody have a quess where bottom is?
Thanks for your response, looks like they lost 500k last quarter but revenue is ramping up nicely. Still with 60k in cash on the books, some dilution is eminent. I like the way they have positioned themselves, I'm a buyer at the right price.
While in the process of due diligence, I couldn't help but notice the the gaming company that KPAY signed an 18 month agreement with only has 1 game listed on their web site. http://acelegends.com/
With the money and stock that they are paying them, you would have thought they could have partnered with a more established gaming company. Has anybody discussed this with IR?
Kinerjapay to Expand its Ecommerce Platform With Launch Of Kinerjagames
•August 11, 2017Comment
KinerjaPay Corp., (KPAY), a digital payment and ecommerce platform, ("KinerjaPay" or the "Company") today announced the plans to expand its digital ecommerce platform with the launch of KinerjaGames. The Company has entered a long-term License Agreement (the "Agreement") with Ace Legends Pte. Ltd ("ACE"), a Singapore-based game developer.
On July 31, 2017, the Company entered into an 18 month license agreement through January 31, 2019, with Ace Legends Pte Ltd. (the “Service Company”) for an exclusive, world-wide license to acquire and market the games currently owned and developed by the Service Company. In consideration for receiving the license and for becoming the game publisher for all of the Service Company’s games indefinitely, the Company agreed to pay to the Service Company $100,000 in four installments of $25,000 each. In addition, the Company agreed to issue to the Service Company 80,000 restricted shares of common stock, which shall be deemed fully paid.
The Company shall pay to the Service Company royalty fees of 21% of all sales generated under the license agreement, which payments shall paid on a quarterly basis. PT KinerjaPay Indonesia, the subsidiary of the Company, shall also pay a monthly fee of $5,000 to the Service Company during the 18 month term of the license agreement for further business development.
Starting some DD, anybody know how much cash is on hand?
Here is a good read on cancer vaccines
http://www.marketwatch.com/story/cancer-vaccines-long-considered-failures-are-hot-again-2017-09-15?siteid=rss&rss=1
IFAI Expo September 26-29 2017
Dr. Mike Hogan, Applied DNA Sciences-Tracking Cotton Authenticity at the Molecular Scale
http://ifaiexpo.com/advancedtextileseducationpresentations/
2017 Textile sustainability conference
MeiLin Wan, our Vice President of Textiles will be speaking on Technology and Traceability Oct. 11
http://textileexchange.org/2017-textile-sustainability-conference/
Derk, the charts say this is headed for 2 bucks, how long before you cut your losses? The last we chatted, it was at 4 bucks, now 3, Jan 1st, probably 2 bucks. This company has nothing going on except management collecting fat paychecks.
With president Trump vowing to eliminate or else greatly reduce the impact of the EPA, will this have a negative effect on the potential market for this company?
Does this company have any revenue producing contracts?
Another good article describing the companies capabilities, Hopefully brings in a paying customer.
http://www.machinedesign.com/industrial-automation/counterfeiting-has-met-its-match-dna-sequence-identification
I think these might have been posted before, but for any new investors out there, these articles provide a good read on the evolving PET & Fertilizer verticals.
http://www.innovateli.com/pet-project-brings-applied-dna-india-world/
http://www.innovateli.com/applied-dna-real-growth-fertilizer/
Interesting tidbit:
http://cmmllp.com/cmm-represents-applied-dna-sciences-inc-agreement-himatsingka-america-inc-bring-molecular-traceability-home-fashions-worldwide/
“One of the thrills of working on Long Island is when you can represent one of its gems,” said Joe Campolo, Managing Partner of Campolo, Middleton & McCormick. “Applied DNA Sciences, under Jim Hayward’s leadership, is a truly innovative company and this deal will help bring product transparency to millions of consumers.”
I'm saying they do not know if DCVAX-L will succeed either so they are hoping for best and planning for the worst. Once they hit data lock, it's all or nothing. I expect data lock in the next few weeks.
One possible reason they are not releasing this information is they want to max out the share count and grab every dollar available first.
Does anybody know how much revenue was generated by the previous agreement with Himatsingka America?
Very helpful, thank you!
This part of the
Press release is confusing me, is this a good thing? Can anybody put this in layman's terms? thanks
In addition to the ppFEV1 measurements taken during the study, an additional ppFEV1 measurement was taken two weeks after patients stopped treatment with alidornase alfa. For this measurement point, a mean decrease in ppFEV1 of -2.7 points was observed from the last alidornase alfa inhalation, while patients taken off Pulmozyme® at the beginning of the trial for two weeks experienced a mean decrease in ppFEV1 of only 0.06 points for the same off treatment duration.
As the company is right now, there is no reason for investors to buy the stock. They need to either offer a dividend or else expand their product line. i was hoping that they would buy CLIR or maybe a competitor. Until something changes, this is dead money.